# Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

> **NCT05231122** · PHASE2 · RECRUITING · sponsor: **Roswell Park Cancer Institute** · enrollment: 80 (estimated)

## Conditions studied

- Ovarian Clear Cell Adenocarcinoma
- Platinum-Sensitive Ovarian Carcinoma
- Recurrent Endometrial Serous Adenocarcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Fallopian Tube Endometrioid Adenocarcinoma
- Recurrent Fallopian Tube Serous Adenocarcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Ovarian Clear Cell Adenocarcinoma
- Recurrent Ovarian Endometrioid Adenocarcinoma
- Recurrent Ovarian Serous Adenocarcinoma
- Recurrent Platinum-Resistant Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Recurrent Primary Peritoneal Clear Cell Adenocarcinoma
- Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
- Recurrent Primary Peritoneal Serous Adenocarcinoma

## Interventions

- **BIOLOGICAL:** Anti-CD40 Agonist Monoclonal Antibody CDX-1140
- **BIOLOGICAL:** Bevacizumab
- **BIOLOGICAL:** Pembrolizumab
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT05231122
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-12
- **Primary completion:** 2026-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-03-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05231122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05231122, "Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05231122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*